Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | PPM1D | O15297 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18301430 | 1.00 | LMNA (0.34) | LMNARIPK1TACR1PPM1DRAB9A | |
| SCHEMBL20471649 | 0.84 | LMNA (0.36) | LMNARIPK1PPM1DRAB9ADPP4 | |
| SCHEMBL17674517 | 0.81 | PPM1D (0.34) | LMNARIPK1PPM1DRAB9ADPP4 | |
| SCHEMBL25282754 | 0.81 | PPM1D (0.34) | LMNARIPK1PPM1DRAB9ADPP4 | |
| SCHEMBL23227860 | 0.80 | PPM1D (0.34) | LMNARIPK1PPM1DRAB9A | |
| SCHEMBL20471654 | 0.80 | PPM1D (0.34) | LMNARIPK1PPM1DRAB9A | |
| SCHEMBL23227952 | 0.80 | PPM1D (0.34) | LMNARIPK1PPM1DRAB9A | |
| SCHEMBL20471798 | 0.80 | PPM1D (0.34) | LMNARIPK1PPM1DRAB9A | |
| SCHEMBL28577698 | 0.79 | PPM1D (0.33) | LMNARIPK1PPM1DRAB9ADPP4 | |
| SCHEMBL18301451 | 0.79 | PPM1D (0.33) | LMNARIPK1PPM1DRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011586-B2 | Heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-07-03 | — | — | US | disclosed |
| US-20180044322-A1 | Novel Heterocyclic Compound, Method for Preparing the Same, and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011586-B2 | Heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | FARS2, AARS1, RNASE1 | LMNA 878/4885RIPK1 3317/4885TACR1 4032/4885 |
| US-20180044322-A1 | Novel Heterocyclic Compound, Method for Preparing the Same, and Pharmaceutical Composition Comprising the Same | FARS2, RNASE1, AARS1 | LMNA 872/4885RIPK1 3420/4885TACR1 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.